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ABSTRACT 
Objective: To decrease the extensive first-pass metabolism of clomipramine (CLM) in the liver by developing and optimizing niosomal transdermal 
formulation of CLM in order to improve its bioavailability.  
Methods: Niosomes were prepared according to 4 × 22 factorial design where surfactant type was set at four levels (Tween 20, Tween 60, Span 20 
and Span 60), surfactant to cholesterol (CH) ratio at two levels (1:1, and 1:0.5) and charge inducing agent (dicetyl phosphate) (DP) at two levels 
(present and absent). Entrapment efficiency (%EE) and release efficiency percentage after 6 h (%RE6) was chosen as dependent variables. CLM 
loaded niosomes were prepared by employing a thin film hydration technique using different non-ionic surfactants (Tween 20, Tween 60, Span 20 
or Span 60), in the presence of CH and a negative charge inducer (DP) in different molar ratios. The prepared niosomes were characterized for 
entrapment efficiency, shape, size, zeta-potential and in vitro drug release.  
Results: The studies demonstrated successful preparation of CLM niosomes. Niosomes showed percentage entrapment efficiency (%EE) of 72.54 ± 
0.37% for optimized formula (F5) which composed of (1:1:0.1 molar ratio of Tween 60, CH and DP) and 25 mg of CLM. The selected formula F5 
(1:1:0.1) was incorporated in gel base of HPMC-K15M (4%) and evaluated through in vitro release. Skin irritancy test performed on albino rats, 
showed no sign of irritation. 
Conclusion: Transdermal delivery of niosomal CLM formulations is expected to improve drug bioavailability, while preferably avoiding undesired 
effects and improving patient compliance. 
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INTRODUCTION 
The delivery of drugs into and through the skin is recognized as an 
effective means of therapy for local dermatologic and systemic 
diseases. In recent years, transdermal delivery of drugs for systemic 
and local effect has gained considerable attention, because it offers 
many advantages over conventional administration such as 
avoidance of first pass metabolism and elimination of 
gastrointestinal irritation resulting in the improvement of patient 
compliance [1]. Gel base formulations make the drug molecules 
more easily to be removed from the system than cream and 
ointment ones [2]. Transdermal delivery is the best suited for drugs, 
which display high toxicity and/or narrow therapeutic windows [3]. 
The proposed advantage of transdermal delivery is the possibility to 
attain sustained and constant drug levels [4]. However, the major 
barrier of the skin is the stratum corneum (SC), the top layer of the 
epidermis. Low molecular weight (≤500 Da), lipophilicity, and 
effectiveness at low dosage are the ideal characteristics of the drugs 
for transdermal delivery. However, many drugs do not possess ideal 
physicochemical properties. Thus, manipulation of the drug or 
vehicle to enhance diffusion through skin becomes necessary [5]. 
Niosomes are such bilayer system containing nonionic surfactants 
and CH. They have longer shelf life, stability and ability to deliver the 
drug at the target site in a controlled or sustained manner which 
enhances bioavailability. Niosomes offer several advantages over 
liposomes such as higher chemical stability, intrinsic skin 
penetration enhancing properties and lower costs [6]. In addition, 
niosomes are versatile carrier systems that can be administered 
through various routes including intramuscular route [7], 
intravenous injection [8], peroral delivery [9], ocular delivery [10], 
pulmonary delivery [11] and transdermal delivery [12-13]. 
Particular efforts have been aimed at using niosomes as effective 
dermal and transdermal drug delivery systems [13-15]. 
Clinical depression is a disturbance of mood that is distinguishable 
from the usual mood fluctuations of everyday life. Suicide is a 
significant risk and up to half of all patients with depression may 
attempt suicide during their lifetime. Risk factors for developing 
depression include female gender and a positive family history[16].  
CLM is a tricyclic antidepressant with actions and uses similar to 
those of amitriptyline. It has antimuscarinic properties and is also a 
potent serotonin reuptake inhibitor. In addition, it is one of the more 
sedating tricyclics. CLM has been estimated to have a plasma 
elimination half-life of about 21 hours. CLM is readily absorbed from 
the gastrointestinal tract, but due to extensive hepatic first-pass 
metabolism to the active metabolite, desmethylclomipramine, less 
than 50% of a dose reach the systemic circulation [16]. Based on the 
aforementioned reasons, the purpose of the current study was to 
prepare CLM encapsulated niosomes in order to be used as 
transdermal carriers for depression treatment. The influence of 
different processing and formulation variables such as surfactant 
structure (Tween 20, Tween 60, Span 20, or Span 60), CH content 
and presence of negatively charged DP on CLM entrapment 
efficiency was demonstrated. Also, particle size, zeta-potential, 
Differential Scanning Calorimetry analysis (DSC) and in vitro drug 
release were evaluated. The selected CLM niosomal dispersion was 
incorporated in gel base of HPMC-K15M (4%) and evaluated 
through in vitro release. 
MATERIALS AND METHODS 
Materials 
CLM was kindly donated by Sigma Pharmaceutical Industries, Egypt- 
S. A. E. CH and DP were purchased from Sigma-Aldrich, USA. 
Polyoxyethylene sorbitan monolautate (Tween 20) was purchased 
from Nice Chemicals pvt. Ltd., Kerala, India. Polyoxyethylene 20 
sorbitan monostearate (Tween 60) was purchased from Alpha 
Chemika, Mumbai, India. Sorbitan monostearate (Span 60) and 
Sorbitan monolaurate (Span 20) were purchased from Oxford 
Laboratory, Mumbai, India. Phosphotungestic acid hydrate was 
purchased from Sigma-Aldrich, Buchs, Japan. Hydroxypropyl 
methylcellulose (HPMC-K15M) was purchased from Tama, Tokyo, 
Japan. Methanol, chloroform, sodium hydroxide, potassium 
dihydrogen phosphate and disodium hydrogen phosphate were 
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purchased from Adwic, El-Nasr Chemical Co., Cairo, Egypt. Spectra/ 
Por dialysis membrane, 12,000–14,000 molecular weight cutoff was 
purchased from Spectrum Laboratories Inc., USA.  
Preparation of CLM Niosomes 
The composition of the tested niosomal formulae are reported in 
Table 1. Niosomes containing CLM were prepared by thin film 
hydration technique. [17-18]. Briefly, 25 mg CLM was weighed 
accurately and dissolved in 10 ml methanol. In a clean, dry, long 
necked quick fit round-bottom flask, a mixture containing non ionic 
surfactant, CH with or without DP, in different molar ratios, were 
completely dissolved in 10 ml chloroform. The drug solution was 
added to the flask getting a mixture of chloroform / methanol 
mixture (1:1, v/v). The organic solvents were slowly evaporated and 
completely removed at 58-60 °C under reduced pressure, using a 
rotary evaporator (Eyela OSB-2000, Japan) at 150 rpm such that a 
thin dry film of the components was formed on the inner wall of the 
rotating flask. The dried thin lipid film was then hydrated with 10 ml 
of phosphate buffer (PB, pH 7.4), by rotating the flask in a water 
bath using a rotavapor under normal pressure in order to ensure 
complete hydration of the film. The niosomes was allowed to 
equilibrate at room temperature, and the niosomal suspension was 
kept in the refrigerator (4 °C) to mature over night [19-20]. 
CLM niosomes were prepared according to 4 × 22 factorial 
experimental design to investigate the influence of formulation 
variables on the entrapment efficiency of the formulations and 
release profile of the drug. In this design, surfactant type (X1), 
surfactant to CH ratio (X2) and charge inducing agent (DP) (X3) 
were selected as independent variables, whereas entrapment 
efficiency (%EE) (Y1) and release efficiency percentage after 6 h 
(RE6%) were chosen as dependent variables. The levels of the 
chosen independent variables were illustrated in Table 2. 
Determination of CLM Entrapment Efficiency %EE 
The proportion of encapsulated CLM was obtained by cooling 
centrifugation (Megafuge 1.0/1.0R, Kendro Laboratory Products 
(Fussex, UK)) of a known aliquot (1 ml) of the prepared niosomal 
suspension at 15,000 rpm for 1 h at 4 °C. The niosomes were 
separated from the supernatant and the amount of the entrapped 
drug was determined by lysis of the niosomal pellet with methanol, 
covered with parafilm to prevent evaporation and sonication to 
obtain a clear solution [21]. The concentration of the drug was 
determined spectrophotometrically (Shimadzu, model UV-1650 PC, 
Kyoto, Japan) by measuring the U. V. absorbance at λmax = 252 nm. 
The entrapment efficiency is defined as follows [22]: 
CLM %EE = (amount of CLM entrapped) / total amount of CLM) x 100 
 
Table 1: CLM niosomal formulae composition (molar ratio) 
Formula Tween 20 Tween 60 Span 20 Span 60  CH  DP 
F1 1 - - - 1 0.1 
F2 1 - - - 1 - 
F3 1 - - - 0.5 0.1 
F4 1 - - - 0.5 - 
F5 - 1 - - 1 0.1 
F6 - 1 - - 1 - 
F7 - 1 - - 0.5 0.1 
F8 - 1 - - 0.5 - 
F9 - - 1 - 1 0.1 
F10 - - 1 - 1 - 
F11 - - 1 - 0.5 0.1 
F12 - - 1 - 0.5 - 
F13 - - - 1 1 0.1 
F14 - - - 1 1 - 
F15 - - - 1 0.5 0.1 
F16 - - - 1 0.5 - 
 
Table 2: Levels of independent variables 
Factors (independent variables) Levels of variables 
 X1: surfactant type  Tween 20 - Tween 60 - Span 20 - Span 60 
 X2: surfactant to CH ratio  1:1 - 1:0.5 
 X3: charge inducing agent (DP) Present – absent 
 
Photomicroscopy and Transmission Electron Microscopy (TEM) 
The formation of niosomal vesicles as well as their morphological 
aspects was evaluated by using photo and transmission electron 
microscopy. 
Various niosomal formulations were examined microscopically at 
magnification of 40× with a binocular microscope (Leica-Queen 
550IW, Germany) equipped with the camera to study their size [23-
24]. A drop of niosome suspension placed on glass slide, examined 
and photographed for morphological evaluation. 
The morphology of hydrated niosome dispersions was also 
examined by Transmission Electron Microscope microscope (model 
JEM-1230, Jeol, Tokyo, Japan) at 70 kV. A drop of dispersion was 
stratified onto a carbon coated copper grid and left to adhere on the 
carbon substrate for about 1 min. The dispersion in excess was 
removed by a piece of filter paper. A drop of 2% phosphotungstic 
acid solution was stratified and, again, the solution in excess was 
removed by a tip of filter paper. The sample was air-dried and 
photographed under TEM [13]. 
Particle size distribution and zeta-potential determinations 
CLM niosomal suspension (100 μl) was diluted to 10 ml with 
distilled water, then subjected at room temperature to photon 
correlation spectroscopy and laser Doppler anemometry (Zetasizer 
ZEN 3600 Nano ZS (Red badge) Malvern Instr., UK) for measurement 
of the particle size [25]; the potential of CLM niosomes was also 
measured and evaluated for surface charge. 
Differential Scanning Calorimetry (DSC) 
DSC experiments were performed using a differential scanning 
calorimeter (DSC 60, Shimadzu, Kyoto, Japan) calibrated with 
indium. Differential scanning calorimetry (DSC) thermograms for 
individual components, CLM, Tween 20, Tween 60, Span 20, Span 
60, CH and DP, as well as drug-loaded niosomes, were investigated. 
Samples (2-4 mg) were placed in flat-bottomed aluminum pan. The 
analysis was performed under nitrogen atmosphere. A heating rate 
of 10 °C /min was employed over a temperature range (30–250) °C 
for Span 60 niosomes and (-100–250) °C for Tween 20, Tween 60 
and Span 20 niosomes.  
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In vitro release of CLM from Niosomes through artificial 
membrane 
The in vitro release of CLM from the prepared niosomes was 
determined, in order to evaluate the effect of various factors used in 
the preparation of CLM niosomes, using the membrane diffusion 
technique [26-27]. After separation of the prepared niosomes by 
centrifugation, an accurately measured quantity of CLM niosomal 
dispersion formulations, equivalent to 25 mg of CLM was 
resuspended in 0.3 ml phosphate buffer (pH 7.4) and transferred to 
a glass cylinder having the length of 10 cm and diameter of 2.5 cm. 
This cylinder was fitted at its lower end with presoaked cellulose 
membrane (Spectra/Por dialysis membrane 12,000–14,000 M wt 
cutoff). The glass cylinder was attached to the shaft of the 
dissolution apparatus and then suspended in the dissolution flask of 
USP dissolution apparatus (NE4-COP Dissolution Testing Station, 
Copley Scientific, Nottingham, UK) containing 100 ml of phosphate 
buffer (pH 5.5) at 32 ± 0.5°C [10]. The glass cylinder was allowed to 
rotate at a constant speed (50 rpm). At predetermined time intervals 
(0.5, 1, 1.5, 2, 3, 4, 5 and 6 hr), 5 ml aliquots of the release medium 
were withdrawn for analysis and replaced with equal volume of 
fresh phosphate buffer (pH 5.5) solution to maintain a constant 
volume [28]. The drug content was determined spectro 
photometrically at λmax 252 nm. The results were the mean values of 
three runs. 
Release efficiency percentage after 6 h (RE6%) was considered as a 
basis for comparison of the dissolution and was calculated based on 
the following equation:  
Release Efficiency (RE %) = º∫ty. dt / y100 t * 100 
Release efficiency is defined as the area under the release curve up 
to a certain time, t, and expressed as a percentage of the area of the 
rectangle described by 100% release in the same time. 
Where the integral is the area under the curve up to release time t 
and y100 is for 100% dissolved drug. For each formula, values of (RE6 
%) were calculated [29]. The mechanism of CLM release from 
niosomal formulations was determined using the following 
mathematical models: zero-order kinetics, diffusion Higuchi kinetics 
and the Korsmeyer-Peppas models. Linearity was detected by linear 
regression analysis. 
The coefficient of determination (R2) was determined in each case. 
The large value of (R2) indicated a superiority of the dissolution 
profile fitting to mathematical equations. 
Incorporation of CLM niosomes in hydroxyl propyl methyl 
cellulose K-15M gel base 
CLM niosomal formula F5 was incorporated in hydroxypropyl 
methyl cellulose K-15M (HPMC-K15M) base (4% w/w) and was 
represented by G1, where the weighed amount of HPMC was 
dissolved gradually in distilled water by the aid of magnetic stirrer 
at medium speed. Stirring was continued until the formation of gel 
base then left overnight for equilibration. Niosomal gel formulations 
were prepared by mixing the niosomal dispersion with the gel base. 
In vitro release studies of CLM niosomal gels through artificial 
membrane 
Accurately measured amounts of CLM niosomal gel formulations, 
equivalent to 25 mg of CLM were placed in a glass cylinder having 
the length of 10 cm and diameter of 2.5 cm. The same procedures 
were followed as previously mentioned. The percent CLM released 
as a function of time is presented as the arithmetic means of three 
measurements (± SD).  
Statistical data analysis 
Analysis of the factorial design was performed using Social Package 
for Statistical Study software (SPSS 17®, SPSS Inc., Chicago, USA). 
Skin irritancy test 
Irritancy test was carried out to determine possible localized 
reaction of the selected formula on the skin since skin safety is of 
prior consideration for transdermal delivery systems [30]. Skin 
irritation studies were carried out on male albino healthy adult rats 
weighing (150–200 g). The animals were kept under standard 
laboratory conditions, with temperature of 25 ± 1 °C and relative 
humidity of 45-60%, with free access to water and food. Rats were 
divided into three groups (each group, n = 3): 
1. Group A: No application (control). 
2. Group B: Niosomal gel without CLM (placebo gel). 
3. Group C: CLM niosomal gel (G1). 
The dorsal surface of the rats was cleaned and hair was removed by 
shaving. CLM niosomal gel (G1) and the unloaded niosomal formula 
dispersed in HPMC-K15M gel (positive control) were placed over the 
skin with the help of the surgical adhesive tap and they were 
removed after 48 h [3,31] and the skin was observed for any visible 
change such as erythema for the next five days. Evaluation was 
carried out using Draize scale [32] on the base as follows:  
0: No erythema development; 1: very slight erythema; 2: well 
defined erythema; 3: moderate to severe erythema; 4: severe 
erythema. 
The animal experiments were conducted in full compliance with 
local, national, ethical and regulatory principles for animal care and 
were approved by the Cairo University Animal Care Committee (S. 
No. PI 1142). 
RESULTS AND DISCUSSION  
The low cost, greater stability and resultant ease of storage of 
nonionic surfactant vesicles [33] have lead to the exploitation of 
these vesicles as alternatives to phospholipid vesicles for the 
enhancement of dermal and/or transdermal bioavailability of drugs 
and substances.  
Entrapment Efficiency %EE 
The entrapment efficiency is the most important parameter from 
pharmaceutical viewpoint in niosomal formulations. A high 
percentage of entrapment would mean less time and effort involved 
in removal of unentrapped material [34]. The entrapment 
efficiencies of all niosomal formulations are reported in Table 3. In 
order to attain high CLM encapsulation efficiency, several factors, 
including the type of surfactant, the ratio of CH added and presence 
of DP were evaluated and optimized. CLM entrapment was 
influenced by the affinity of the drug for the niosome material, the 
thickness of the niosome bilayers, the drug solubility in water, and 
the compatibility between the drug and niosome material [35]. 
Factors affecting entrapment efficiency of CLM 
A full 4 × 22 factorial design was applied to evaluate the effect of 
surfactant type (X1), surfactant to CH ratio (X2) and charge inducing 
agent (DP) (X3) on the entrapment efficiency (%EE). Analysis of 
factorial design demonstrated that the surfactant type had a 
significant effect on the entrapment efficiency (p < 0.05) as shown in 
Fig. 1. The entrapment efficiency of different surfactants could be 
ranked as follows: Tween 60 > Span 60 > Tween 20 > Span 20. 
The entrapment efficiencies for niosomes prepared using Tween 60 
were superior to those prepared using Tween 20. This shows that 
the vesicles obtained from stearyl (C18) chain surfactants (Tween 
60) produce higher entrapment efficiencies than surfactants with 
lauryl (C12) chain (Tween 20), as the length of alkyl chain is a 
crucial factor of permeability. Thus, long chain surfactants produce 
high entrapment [36]. Additionally, the alkyl chain length influences 
the hydrophilic-lipophilic balance (HLB) value of the surfactant [37]. 
The lower the HLB of the surfactant the higher will be the drug 
entrapment efficiency and stability as in the case of niosomes 
prepared using Tween 60 (HLB = 14.9), whilst Tween 20 with a high 
HLB of 16.7, showed low entrapment efficiency. Our results are 
dissimilar to the results reported by Ruckmani K. and Sankar V., 
2010 which indicate that the higher the HLB of the surfactant, the 
higher will be the entrapment efficiency [38]. 
It is clear that CLM niosomes prepared utilizing Span 60 revealed 
higher entrapment efficiencies than those prepared using Span 20. 
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The higher entrapment may be due to the solid nature, 
hydrophobicity and high phase transition temperature of the Span 
60 [39]. Spans 60 has the highest transition temperature (Tc = 53 
◦C) amongst all spans (16 ◦C for Span 20, 42 ◦C for Span 40 and -12 
◦C for Sp 80) [40]. The span having the higher phase transition 
temperature provides the higher entrapment for the drug and vice 
versa [36, 39]. These findings are in agreement with previous 
researchers' work, where the increase in the alkyl chain length span 
60 (C18) > Span 20 (C12) led to increase in the encapsulation 
efficiency (%EE) [41-42]. Additionally, the lower the HLB of the 
surfactant the higher will be the drug entrapment efficiency and 
stability [43-44]. In the present study, niosomes prepared using 
Span 60, HLB = 4.7, exhibited higher (%EE) compared to Span 20 
with a higher HLB value, namely; 8.6.  
Many non-ionic surfactants form vesicles when CH is included in the 
bilayer to the level of 30-50 mole% [45]. CH imparts rigidity to 
vesicles, which is very important under severe stress conditions 
[46]. CH improves the fluidity of the bilayer membrane and 
improves the stability of the bilayer membrane in the presence of 
biological fluids such as blood/plasma [47]. Depending on the data 
obtained from our factorial design, surfactant to CH ratio had a 
significant effect on the entrapment efficiency (p < 0.05). Higher 
entrapment was found at surfactant / CH molar ratio of 1:1. The 
effect of CH molar ratios on entrapment efficiency is demonstrated 
in Table 3. High entrapment was found in Tween 20 and Tween 60 
formulation at CH /surfactant molar ratio of 1:1. The interaction of 
CH with Span 60 in the bilayer of niosomes is due to hydrogen 
bonding [46]. 
Inclusion of CH increases the viscosity of the formulation indicating 
more rigidity of the bilayer membrane. Moreover, drug partitioning 
will occur more easily in highly ordered systems of surfactant and 
CH. The ability of the lamellar surfactant phase to accommodate 
drug, depends upon the structure of the surfactant phase [48]. 
However entrapment efficiency increased with decreased CH content 
in Span 20 and Span 60 formulations. These results are in a good 
agreement with that reported by Muzzalupo et al., 2005, where the 
best encapsulation efficiency was obtained when niosomes were made 
up of surfactant and CH at the molar ratio of 2:1 [49]. 
 
Table 3: % Entrapment efficiency %EE, Particle size, Zeta potential and RE6% of CLM niosomal formulations 
Niosomal Formulation %Entrapment efficiency 
(%EE ±S. D.) 
Particle size (nm) 
(mean ± S. D.) 
Zeta potential (mV) (mean ± S. D.) %RE6a ± SD 
F1 36.26 ± 1.87 434.40 ± 1.82  -41.70 54.97 ± 1.05 
F2 35.17 ± 1.54  299.80 ± 0.30  -17.80 62.83 ± 1.97 
F3 29.59 ± 1.37  220.20 ± 1.81   -38.40 72.95 ± 2.45 
F4 34.95 ± 0.79 141.80 ± 1.49  -14.00 77.70 ± 1.17 
F5 72.54 ± 0.37 825.00 ± 0.31  -32.80 29.72 ± 0.06 
F6 46.03 ± 1.71 615.10 ± 1.56 -9.27 24.73 ± 0.75 
F7 32.50 ±1.48 538.90 ± 0.93 -41.50 39.57 ± 1.26 
F8 43.34 ± 1.40 488.70 ± 0.33 -26.60 50.43 ± 1.45 
F9 4.30 ± 0.16 240.60 ± 0.81 -64.50 ND 
F10 25.53 ± 1.61 197.10 ± 0.27 -46.80 ND 
F11 9.69 ± 0.45 193.50 ± 0.68 -54.10 ND 
F12 42.1 ± 2.38 180.40 ± 1.42 -37.00 ND 
F13 26.92 ± 1.82 879.80 ± 0.55 -37.10 9.17 ± 1.37 
F14 35.71 ± 1.90 261.10 ± 0.17 -35.80 14.86 ± 1.34 
F15 29.07 ± 1.57 548.00 ± 0.76 -69.10 15.21 ± 1.37 
F16 42.21 ± 2.81 255.00 ± 0.82 -44.40 16.52 ± 1.29 
a %RE6: Release Efficiency percentage after 6 h. 
 
It is obvious from Fig.1 that DP had a great effect on the CLM 
entrapment (p < 0.05). . In case of niosomes composed of Span 20 
(F9–F12) or Span 60 (F13–F16), incorporation of DP was found to 
decrease the encapsulation efficiency of CLM. These results come in 
accordance with those reported for the incorporation of charge 
inducing agents into acetazolamide liposomes [50].  
However, contrary to previous results, In case of niosomes 
composed of Tween 20 (F1–F4) or Tween 60 (F5–F8), the 
incorporation of DP was found to increase the entrapment efficiency 






Fig. 1: Effect of surfactant type, surfactant to CH ratio and DP on 
the Entrapment Efficiency %EE 
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This increase could be explained by the fact that CH in the presence 
of DP was more efficiently able to stabilize the structure of the 
niosomal membrane in a molar ratio of 1:1 (non-ionic surfactant: 
CH) [33]. These results show that inclusion of DP alters the 
entrapment; but that it also depends upon the alkyl side-chain of the 
surfactant and CH molar ratio. 
Photomicroscopy and Transmission Electron Microscopy (TEM) 
The photomicrographs (x40) of CLM niosomes prepared by reverse 
phase evaporation technique is shown in Fig. 2.  




Fig. 2: Photomicrographs of CLM-loaded niosomes, magnification power 40× 
 
Negative stain transmission electron micrographs of CLM niosomes 
F5 composed of Tween 60, CH and DP in a 1:1:0.1 molar ratio and 
F14 composed of Span 60 and CH in a 1:1 molar ratio are shown in 
Fig. 3 A, B and C respectively.  
It is demonstrated that the vesicles are well identified and present in 
a nearly perfect sphere-like shape having a large internal aqueous 
space relative to the sphere diameter [51]. 
 
 
F5 (A)     F5 (B)    F14 (C)  
Fig. 3: Negative stain transmission- electron micrographs of CLM -loaded niosomes F5 (A) [Mag. 8000x]; F5 (B) [Mag. 815000x]; F14 (C) 
[Mag. 120000x] 
 
Particle size distribution and zeta-potential determinations 
Results of particle size analysis showed that the niosomal 
formulations prepared using Tween 20, Tween 60, Span 20 or Span 
60, with or without charge inducing agent, at both molar ratios are 
in the nano-size range. Niosomal formulations composed of Tween 
60 (F5–F8) are larger in size than niosomes prepared using Tween 
20 (F1–F4). Tween 60 has longer alkyl chain compared to Tween 20 
and it was reported that surfactants with longer alkyl chains 
generally give larger vesicles [52]. This would account for the higher 
entrapment efficiencies obtained with Tween 60 niosomes. The 
same observation was recorded when particle size of niosomal 
formulations composed of Span 60 were compared to particle size of 
niosomal formulations composed of Span 20 prepared. Results of 
particle size analysis showed that, as the concentration of CH 
increases, the particle size of different formulations also increases, 
which was may be due to the formation of rigid bilayer structure 
[53] as illustrated in Table 3. 
When zeta potential was studied to understand the surface charges 
of the vesicles it was noticed that the zeta potential values of neutral 
and negatively charged niosomal formulations, prepared using 
Tween 20, Tween 60, Span 20 or Span 60, of either molar ratio, falls 
in the zone in which the colloidal system dispersion is stable (more 
negative than -30 mV). The zeta potential of the niosoml 
formulations prepared using DP were more negatively charges than 
neutral niosoml formulations, the values of zeta potential of 
niosomal vesicles are represented in Table 3. 
Differential Scanning Calorimetry (DSC) 
DSC for the individual constituents of niosomes, Tween 20, Tween 
60, Span 20, Span 60, CH, DP and CLM shows thermal peaks at 45.08 
°C, 25.13 °C, 15.41 °C, 56.34 °C, 149.00 °C, 48.35 °C and 194.04 °C, 
respectively, corresponding to their melting temperatures as shown 
in Fig. 4. 
Drug loaded niosomal formulations showed broad transitions which 
are characteristic for lipid mixtures containing CH, signifying good 
interaction of all components forming the bilayers of niosomes [54]. 
Fig. 4 A, B, C and D shows that the DSC thermograms of niosomal 
formulations prepared using either Tween 20, Tween 60, Span 20 or 
Span 60 with or without DP, using either molar ratio, reveal the 
effect of niosomal formulation on the individual constituents of 
niosomes as well as the effect of entrapped drug by changing the 
thermodynamic parameters of the thermal peaks. Fig. 4 (D) shows 
that both transition temperature and transition energy of Span 60 
peak of niosomal formulation (F16) is less than that of pure Span 60.  
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A DSC thermogram of loaded niosomes exhibit disappearance of 
characteristic exothermic peak of CLM. The absence of the melting 
endotherm of CLM and shifting and/or broadening of the 
endotherms of surfactant bilayers of niosomes suggests possible 
interaction of CLM with bilayer components and can account for the 
enhanced entrapment of CLM into these formulations [51,55]. 
 
 
(A)        (B) 
 
(C)        (D) 
Fig. 4: Differential Scanning Calorimetry (DSC) measurements of niosome components and CLM loaded niosomal formulae (A) F2; (B) F16; 
(C) F9; (D) F5 
 
In vitro Release of CLM from Niosomes  
The release profile of CLM from niosomal formulations prepared 
using Tween 20, Tween 60 or Span 60 is graphically illustrated in 
Figs. 5, 6 and 7, respectively. The release efficiency percentage after 
6 h (%RE6) of the prepared niosomal vesicles are shown in Table 3. 
From the results, it is obvious that niosomal CLM formulations 
showed slower release rate than CLM solution.  
Analysis of factorial design demonstrated that the surfactant type 
had a significant effect on the release efficiency percentage after 6 h 
(p < 0.05) as shown in Fig. 8. The release efficiency of different 
surfactants could be ranked as follow: Tween 20 > Tween 60 > Span 
60. This can be explained by the fact that niosomes exhibit an alkyl 
chain length-dependent release and the higher the chain length, the 
lower the release rate [45].  
 
 
Fig. 5: Percentage release profile of CLM from niosomal 
formulae (F1–F4) 
 




Fig. 7: Percentage release profile of CLM from niosomal 
formulae (F13–F16) 
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By inspection of the data, it could be concluded that niosomal 
formulations of Tween 20, Tween 60 or Span 60 with CH in a molar 
ratio 1:1 (non-ionic surfactant: CH) (F1, F2, F5, F6, F13, F14) showed 
slower release rate of the drug when compared to niosomes 
composed of (non-ionic surfactant: CH) in a molar ratio 1:0.5. 
Increasing CH markedly reduces the efflux of the drug. Inclusion of 
CH fills the pores in vesicular bilayers and abolishes the gel-liquid 
phase transition of liposomal and niosomal systems resulting in 





Fig. 8: Effect of surfactant type, surfactant to CH ratio and DP on 
the %Release efficiency 
This confirms that CH in the formulation acts as a membrane 
stabilizing agent that helps to sustain drug release [38]. Cocera et 
al., 2003 reported that CH produced an optimum hydrophobicity 
which decreased the formation of the transient hydrophilic holes, by 
decreasing membrane fluidity, responsible for drug release through 
liposomal layers [56]. It is obvious from Fig. 8 that DP had a great 
effect on CLM release (p < 0.05). By comparing the release data of 
CLM niosomes containing DP with that of DP free-niosomes, it is 
clear that the release is retarded in presence of DP. This comes in 
accordance with the effect of DP in stabilizing the niosomal 
membrane structure, rendering it less permeable [57]. 
Linear regression analysis for the release data of CLM from 
niosomes (F1–F16) is tabulated in Table 4. The data showed that the 
CLM is released following diffusion controlled mechanism for 
formulae (F1 and F5), zero release kinetics (for formulae F4, F6, F7, 
F13, F15 and F16) and Korsmeyer-Peppas for F2, F3, F8 and F14. 
The n value from the Korsmeyer-Peppas model for CLM niosomal 
formulations was > 0.54 indicating anomalous diffusion mechanism 
with erosion, except for F3, F13 and F14 between 0.23 and 0.54 
which confirms the Fickian type diffusion [58]. 
In vitro release studies of CLM niosomal gels through artificial 
membrane 
The release profile of CLM from the prepared niosomal gel in 
Sorensen's phosphate buffer of pH 5.5 is graphically represented in 
Fig. 9. It was evident that the incorporation of the drug in niosomes 
resulted in delayed release which was further delayed in case of 
niosomal gel due to formation of an additional diffusion barrier to 
drug release [59]. In case of the prepared niosomal gels a noticeable 
and gradual control of release behavior of CLM could be observed 
during the whole release run (19.00%) of CLM was released from G1 
after 6 h. 
Skin irritancy test 
No obvious erythema, oedema or inflammation was observed on 
rats’ skin after one week of application of the selected formulation. 
Thus it could be concluded that neither the surfactant used nor the 
CLM used in the niosomal formulation as well as the other excipients 
were non-irritant to the skin. 
 
Fig. 9: In-vitro release profile of CLM from niosomal gel in 
Sorensen's phosphate buffer of pH 5.5 
 
Table 4: Kinetic analysis of release data of CLM through artificial membrane 
Niosomal Formulation Zero order R2 Higuchi diffusion R2 Korsemeyer- Peppas R2 Release Order n 
F1 0.989 0.994 0.993 Diffusion 0.759 
F2 0.942 0.987 0.998 Peppas 0.613 
F3 0.869 0.941 0.955 Peppas 0.485 
F4 0.987 0.985 0.982 Zero order 0.641 
F5 0.993 0.997 0.985 Diffusion 1.393 
F6 0.999 0.986 0.998 Zero order 0.820 
F7 0.999 0.974 0.996 Zero order 0.929 
F8 0.991 0.989 0.994 Peppas 0.789 
F13 0.996 0.978 0.978 Zero order 0.439 
F14 0.994 0.988 0.999 Peppas 0.471 
F15 0.993 0.954 0.969 Zero order 0.647 
F16 0.983 0.932 0.944 Zero order 0.549 
R2= coefficient of determination. 
CONCLUSION 
From the presented study, it is clear that CLM niosomes were 
successfully prepared by the thin film hydration technique. 
Surfactant structure, CH content and the presence of negative charge 
inducer (DP) altered the entrapment efficiency %EE and release rate 
from CLM niosomes. Niosomal formulations characterization using 
TEM showed the spherical shape of the prepared niosomes. DSC 
studies gave evidence of possible interaction of CLM with niosomal 
components. Incorporation of drug in niosomes resulted in delayed 
release which was further delayed in case of niosomal gel. CLM 
niosomal gel showed no irritation to rat skin. Accordingly, 
transdermal delivery of niosomal CLM formulations is expected to 
improve drug bioavailability, while preferably avoiding undesired 
effects and improving patient compliance. 
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